Cargando…

Health-Related Quality of Life in Focal Segmental Glomerular Sclerosis and Minimal Change Disease: A Qualitative Study of Children and Adults to Inform Patient-Reported Outcomes

RATIONALE & OBJECTIVE: Assessment of how patients feel and function is needed for clinical care and research for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD). The objective of this study was to develop a patient-reported outcome assessment appropriate for use in chi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carlozzi, Noelle E., Massengill, Susan F., Trachtman, Howard, Walsh, Liron, Singhal, Neena, LaVigne, Joseph M., Miner, Jennifer A., Desmond, Hailey E., Lynam, Christian, Gipson, Debbie S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350833/ https://www.ncbi.nlm.nih.gov/pubmed/34401716 http://dx.doi.org/10.1016/j.xkme.2021.01.013

Ejemplares similares

Association between Psychiatric Disorders and Glomerular Disease
por: Desmond, Hailey E., et al.
Publicado: (2021)

Developing an Edema Clinician-Reported Outcome Measure for Nephrotic Syndrome
por: Gipson, Debbie S., et al.
Publicado: (2023)

The Development and Use of an EHR-Linked Database for Glomerular Disease Research and Quality Initiatives
por: Eikstadt, Richard N., et al.
Publicado: (2021)

Complement Activation in Patients with Focal Segmental Glomerulosclerosis
por: Thurman, Joshua M., et al.
Publicado: (2015)

Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design
por: Walsh, Liron, et al.
Publicado: (2021)

Refractory Minimal Change Disease and Focal Segmental Glomerular Sclerosis Treated With Anakinra
por: Angeletti, Andrea, et al.
Publicado: (2021)

Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design
por: Trachtman, Howard, et al.
Publicado: (2011)

Diverse Alterations of Glomerular Capillary Networks in Focal Segmental Glomerular Sclerosis
por: Morita, Megumi, et al.
Publicado: (2022)

Histological heterogeneity of glomerular segmental lesions in focal segmental glomerulosclerosis
por: Taneda, Sekiko, et al.
Publicado: (2011)

Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)
por: Komers, Radko, et al.
Publicado: (2017)

Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group
por: Trachtman, Howard, et al.
Publicado: (2015)

Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis
por: Lin, Li, et al.
Publicado: (2021)

Comparing Kidney Health Outcomes in Children, Adolescents, and Adults With Focal Segmental Glomerulosclerosis
por: Gipson, Debbie S., et al.
Publicado: (2022)

Comparison of Glomerular Transcriptome Profiles of Adult-Onset Steroid Sensitive Focal Segmental Glomerulosclerosis and Minimal Change Disease
por: Tong, Jun, et al.
Publicado: (2015)

The Role of Rituximab in Primary Focal Segmental Glomerular Sclerosis of the Adult
por: Tedesco, Martina, et al.
Publicado: (2022)

NephCure Accelerating Cures Institute: A Multidisciplinary Consortium to Improve Care for Nephrotic Syndrome
por: Gipson, Debbie S., et al.
Publicado: (2017)

The Treatment of Minimal Change Nephropathy and Focal Segmental Glomerulosclerosis
por: Mason, P D
Publicado: (1997)

The Treatment of Minimal Change Nephropathy and Focal Segmental Glomerulosclerosis
por: Milford, D V
Publicado: (1997)

A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis
por: Trachtman, Howard, et al.
Publicado: (2011)

Glomerular Endothelial Cell Injury and Focal Segmental Glomerulosclerosis Lesion in Idiopathic Membranous Nephropathy
por: Morita, Megumi, et al.
Publicado: (2015)

Changing the Paradigm for the Treatment and Development of New Therapies for FSGS
por: Spino, Cathie, et al.
Publicado: (2016)

Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis
por: Komers, Radko, et al.
Publicado: (2020)

Glomerular capillary C3 deposition as a risk factor for unfavorable renal outcome in pediatric primary focal segmental glomerular sclerosis
por: Peng, Yingchao, et al.
Publicado: (2023)

Glomerular parietal epithelial cells contribute to adult podocyte regeneration in experimental focal segmental glomerulosclerosis
por: Eng, Diana G., et al.
Publicado: (2015)

Novel parietal epithelial cell subpopulations contribute to focal segmental glomerulosclerosis and glomerular tip lesions
por: Kuppe, Christoph, et al.
Publicado: (2019)

Identification of glomerular and podocyte-specific genes and pathways activated by sera of patients with focal segmental glomerulosclerosis
por: Otalora, Lilian, et al.
Publicado: (2019)

Cyclophosphamide as a Treatment for Focal Segmental Glomerular Sclerosis Recurrence in a Kidney Transplant Patient
por: Al-Jehani, Mariann H., et al.
Publicado: (2021)

Nephrotic syndrome with focal segmental glomerular lesions unclassified by Columbia classification; Pathology and clinical implication
por: Ozeki, Takaya, et al.
Publicado: (2021)

Later Response to Corticosteroids in Adults With Primary Focal Segmental Glomerular Sclerosis Is Associated With Favorable Outcomes
por: Rood, Ilse M., et al.
Publicado: (2021)

Treatment of Recurrent Focal Segmental Glomerulosclerosis in Pediatric Kidney Transplant Recipients: Effect of Rituximab
por: Sethna, Christine, et al.
Publicado: (2011)

Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial
por: Trachtman, Howard, et al.
Publicado: (2023)

Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease
por: Oh, Gia J., et al.
Publicado: (2019)

Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis
por: Gipson, Debbie S., et al.
Publicado: (2020)

Responsiveness of the PROMIS® measures to changes in disease status among pediatric nephrotic syndrome patients: a Midwest pediatric nephrology consortium study
por: Selewski, David T., et al.
Publicado: (2017)

Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease
por: Chebotareva, Natalia V., et al.
Publicado: (2022)

Focal segmental glomerular sclerosis, a type of intractable chronic glomerulonephritis, is a stem cell disorder
Publicado: (1994)

Autosomal Dominant Tubulointerstitial Kidney Disease—Uromodulin Misclassified as Focal Segmental Glomerulosclerosis or Hereditary Glomerular Disease
por: Chun, Justin, et al.
Publicado: (2020)

CASK, the Soluble Glomerular Permeability Factor, Is Secreted by Macrophages in Patients With Recurrent Focal and Segmental Glomerulo—Sclerosis
por: Zhang, Xiaomeng, et al.
Publicado: (2020)

Predictive value of sub classification of focal segmental glomerular sclerosis in Oxford classification of IgA nephropathy
por: Yu, Fang, et al.
Publicado: (2021)

Clues to Glomerular Cell Chatter in Focal Segmental Glomerulosclerosis: Via Endothelin-1/ET(A)R
por: Lassén, Emelie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kur3chpu953met3k76o8d6rpna